As part of their weekly show, Biotech Banter, Fool contributor Brian Orelli and health-care bureau chief Max Macaluso occasionally run a segment highlighting a biotech. This week's honor goes to Agios Pharmaceuticals (NASDAQ:AGIO), which IPOed last year.
The company zoomed up 28% on Monday after presenting positive data on its cancer drug AG-221 at the American Association for Cancer Research over the weekend. In a small Phase 1 trial, six of seven evaluable patients with acute myeloid leukemia responded to AG-221, including three complete remissions and two complete remissions with incomplete platelet recovery. That's pretty amazing, considering these patients had already failed previous treatments.
Agios' pipeline is in the relatively early stages, with a couple of products, including AG-221, licensed to Celgene (NASDAQ:CELG). To justify its $1.4 billion market cap, the drugs will have to work in later-stage trials, but so far everything looks promising.
Watch the following video for Brian's and Max's takes on Agios Pharmaceuticals.
Brian Orelli has no position in any stocks mentioned. Max Macaluso owns shares of Celgene. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
5 of the Most Hated Biotech Stocks on the Market: Are They Buys?
Short-sellers have piled on Agios, Insys, Intercept, Lexicon, and Myriad Genetics. But are they wrong?
3 Debt-Free Clinical-Stage Biotech Stocks That Are Swimming in Cash
Funding isn't a big concern for these three drug developers.
Why Agios Pharmaceuticals Sank 34.4% in 2016
It was a roller-coaster year for investors in the clinical-stage biotech. Here's a review of the year's key headlines that caused shares to drop.